Uradex

Quick links to important sections

Uradex

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Uradex

Quick Facts

Property Description
Active Ingredient Furosemide
Form Tablet, Oral Solution, Injectable Solution
Pharmacological Class Loop Diuretic (High-Ceiling Diuretic)
Common Purpose Reduction of excess fluid volume (Diuresis)
Origin Synthetic compound (Sulfonamide derivative)

What Type of Medicine is Uradex? (Identity and Classification)

Uradex is a synthetic, prescription-only medicine whose active component, Furosemide, definitively classifies it as a loop diuretic, which is widely regarded as the most potent diuretic type. Furosemide is chemically a benzene-sulfonamide derivative, distinguishing it from other diuretic sub-classes. This compound is clinically recognized for its rapid onset of action. The drug is categorized as an essential medicine, underscoring its broad application in managing fluid-related issues.

Composition and General Forms of Uradex

The composition of Uradex is that of a single active ingredient product, relying exclusively on Furosemide for its therapeutic effects. The medication is prepared in several pharmaceutical preparations to ensure flexibility in delivery. These include the solid dosage forms, specifically tablets, intended for the oral route of administration, and a sterile injectable solution (parenteral formulation) used for the intravenous or intramuscular route. These high-level forms, incorporating essential solid excipients or an aqueous vehicle, establish the physical identity of the product. The availability of Uradex in an injectable solution highlights its differentiation from many oral-only diuretics, allowing its use when rapid, controlled removal of fluid volume is necessary.

The General Purpose of Uradex (Core Benefit)

The general purpose of Uradex is to achieve rapid and potent diuresis, which is the physiological process of increasing urine output to clear excess fluid. By facilitating the substantial loss of water and necessary salts from the body, Uradex reduces overall bodily fluid volume. This core function serves to relieve the accumulation of unwanted fluid, or edema, typically seen in states of fluid overload, and to address the physical consequences of generalized fluid retention.

What side effects are possible with Uradex?

Possible Side Effects and Safety Information

The safety profile of Uradex is officially documented by government regulatory bodies and is primarily defined by the adverse reactions observed in clinical use, focusing heavily on ocular effects.

Frequency-Classified Adverse Reactions

Side effects are categorized by how often they occur, based on regulatory standards. The most frequently reported adverse reactions are related to the eye:

  • Very Common (may affect more than 1 in 10 people):

    • Increased intraocular pressure (IOP)
    • Conjunctival hemorrhage
    • Cataract (specifically in patients with an intact lens)
  • Common (may affect up to 1 in 10 people):

    • Ocular hypertension
    • Eye pain
    • Vitreous detachment
    • Headache

Serious Adverse Reactions

Regulatory documents highlight the potential for serious and clinically significant adverse events requiring immediate medical attention, including endophthalmitis, retinal detachment, and glaucoma. The management of elevated IOP may necessitate subsequent surgical procedures.

Safety Restrictions and Limitations

Uradex is formally contraindicated (should not be used) in patients with specific pre-existing conditions, due to increased risk:

  • Active or suspected infections of the eye or surrounding area (e.g., most viral diseases of the cornea, active epithelial herpes simplex keratitis).
  • Glaucoma with a cup to disc ratio greater than 0.8.
  • A torn or ruptured posterior lens capsule, due to the risk of medication migration.
  • Known hypersensitivity to any component of the product.

Safety Monitoring

Following administration, official documentation mandates that patients be monitored for potential complications, including checking the intraocular pressure and assessing for signs of endophthalmitis.

Overdose and Emergency Response

Overdose and When to Seek Help

Uradex overdose information, as documented in official regulatory sources, describes severe manifestations stemming from excessive diuresis and the resulting fluid and electrolyte depletion.

Documented Overdose Manifestations

Overdose may present with symptoms directly related to volume loss, including profound dehydration, hypotension (low blood pressure), and significant weakness or lethargy. Physiological findings are defined by severe electrolyte imbalance, primarily hypokalemia (low potassium), hyponatremia (low sodium), and hypochloremic alkalosis, alongside elevated blood urea nitrogen leading to azotemia.

Severe Outcomes and Required Actions

The regulatory profile outlines serious outcomes such as circulatory collapse, vascular thrombosis, and the risk of life-threatening cardiac arrhythmias due to metabolic disturbances. In patients with pre-existing hepatic cirrhosis, rapid fluid shifts carry the documented risk of precipitating hepatic encephalopathy or coma. Official guidance mandates to seek immediate medical attention or call emergency services if severe symptoms occur, such as collapse, seizing, or difficulty breathing.

Management and Antidote Status

The official management of overdose is defined as strictly supportive and symptomatic treatment, focusing on the mandatory replacement of excessive fluid and electrolyte losses. No specific antidote is known for Uradex overdose. Close hospital monitoring, including frequent determination of serum electrolytes and blood pressure, is required.

Therapeutic Uses of Uradex

What Uradex Treats: Main Uses and Benefits

Uradex (Furosemide) is generally used in clinical situations involving the reduction of excess fluid volume from the body, providing supportive symptomatic relief across several chronic and acute conditions. Furosemide is commonly used to treat swelling (edema) caused by various medical problems, including kidney, liver, and heart disease, and to help manage high blood pressure.

Relief from Swelling and Systemic Fluid Retention

The medication is applicable in conditions marked by heightened symptoms, such as Congestive Heart Failure, Chronic Kidney Disease, and Cirrhosis of the Liver, where it assists with managing fluid accumulation and its associated discomfort. It is also considered relevant in clinical settings involving acute episodes with fluid buildup, such as Acute Pulmonary Edema.

Quick Fact: Relief for Systemic Fluid Buildup

Indication Type Primary Symptom Addressed Patient Benefit
Chronic Organ Stress Swelling and generalized edema Easing physical discomfort
Acute Congestion Difficulty breathing (Dyspnea) Supports functional stability
Volume-Dependent HTN Elevated systemic pressure Manages long-term symptom burden

Uradex contributes to the lowering of systemic pressure through its action on fluid volume and supports the management of volume overload. This supportive relief helps patients cope more steadily with symptom fluctuations and assists with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Uradex (Furosemide) is officially established for use in adults, children, and infants to treat fluid accumulation (edema). However, regulatory labeling strictly defines conditions and populations under which the medicine must not be used.

Absolute Contraindications

Uradex is prohibited for patients with known hypersensitivity to Furosemide or a history of sulfonamide allergy. Absolute contraindications also include states of severe fluid or electrolyte imbalance, such as anuria (no urine output), severe hypovolaemia, dehydration, severe hypokalaemia, or hyponatraemia. Patients in a comatose state or with hepatic encephalopathy must not use this medicine. Use is also strictly contraindicated for women who are breastfeeding.

Restricted and Conditional Use

Specific populations require caution and careful monitoring. Elderly patients are susceptible to excessive fluid loss and require restricted dosing. Use is limited in patients with partial obstruction of urinary outflow and those with hypoproteinemia, which necessitates careful dose titration. The use of Uradex during pregnancy is limited to short periods only and requires careful medical review. Use is not recommended in newborns with jaundice due to specific risks documented in official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Furosemide (Uradex) interaction patterns are documented in regulatory labels, focusing on additive effects and altered drug exposures. These interactions are classified as pharmacokinetic and pharmacodynamic in nature.

Interaction Category Interacting Agents and Official Description
Additive Toxicities Co-administration with ototoxic drugs (e.g., aminoglycoside antibiotics) or nephrotoxic drugs increases the risk of organ injury. This risk is notably heightened in patients with severe renal impairment.
Exposure Modification Furosemide reduces the renal clearance of lithium, which can lead to increased plasma lithium levels and toxicity. Sucralfate reduces the absorption of Furosemide.
Pharmacodynamic Effects NSAIDs can reduce the diuretic effect of Furosemide. Co-administration with other antihypertensive agents or alcohol may result in additive blood pressure lowering.

Certain combinations require specific administration rules. Due to reduced absorption, Furosemide must be administered at least two hours apart from sucralfate. Furthermore, use with substances that promote potassium loss, such as corticosteroids or licorice, requires consideration due to the enhanced risk of severe hypokalemia.

Mechanism of Action

Targeted Inhibition of the NKCC2 Ion Transporter

Uradex's active mechanism begins with the non-competitive inhibition of the Sodium-Potassium-Chloride Cotransporter 2 (, NKCC2), a transporter located exclusively on the luminal surface of the thick ascending limb of the Loop of Henle . By blocking the reabsorption of Na^+, K^+, and Cl^- ions, the drug initiates a cascade that prevents the kidney from reclaiming these crucial electrolytes.


Disrupting the Kidney's Osmotic Concentrating Pathway

This initial molecular blockade triggers the functional disruption of the countercurrent multiplier system, which is the kidney's mechanism for conserving water. Because the NKCC2 transporter is inhibited, a high concentration of solutes remains in the tubular fluid, thereby abolishing the osmotic gradient in the renal medulla that typically drives the reabsorption of water downstream. This interference with water-reclaiming pathways results in a rapid and substantial increase in urinary output, leading to a significant net loss of water and solutes.


Mechanism Constraint: Dependence on OAT1 Secretion

The entire mechanism is fundamentally dependent on the active transport of the Furosemide molecule from the blood into the renal tubule via the Organic Anion Transporter 1 (, OAT1). The rate and efficiency of this secretion step determine how quickly the drug reaches its NKCC2 target, which is the key mechanistic factor determining the kinetics of the physiological response.

Dosage and Administration Information

Uradex (Furosemide) usage is guided by specific administration instructions and dosage schedules. The medicine is administered through the oral route (tablet or solution) for maintenance use and via the parenteral route (Intravenous (IV) or Intramuscular (IM) injection) for acute situations or when oral absorption is impaired.

Official Dosing and Frequency

Standard oral dosing for managing fluid retention (edema) typically starts in the range of 20 mg to 80 mg, administered as a single daily dose or divided into two doses. Dose adjustments must be made gradually, with increases occurring no sooner than 6 to 8 hours after the previous oral dose. For cases requiring rapid action, the initial IV dose is generally 20 mg to 40 mg. For acute pulmonary edema, a 40 mg IV dose is specified, which may be increased to 80 mg if the initial response is insufficient within one hour.

Administration Requirements

Feature Administration Summary
IV Rate Bolus injection must be administered slowly over 1 to 2 minutes; continuous infusion rate must not exceed 4 mg per minute.
Timing (Oral) Doses are generally recommended to be taken on an empty stomach.
Timing Constraint Must not be taken within 2 hours of Sucralfate to avoid reduced absorption.

Population-Specific Use

Dosage recommendations include specific considerations for vulnerable groups. For pediatric patients, the dose is calculated based on body weight, starting at 1 mg/kg. In older adults, therapy should typically begin at the lower end of the dosing range with slower titration due to altered drug elimination profiles. Furthermore, for the injectable solution, preparations must be visually inspected and must not be mixed with solutions that have a pH below 5.5, which is a critical procedural constraint.

Recent Clinical Evidence

Research Evidence / Overview of Studies

General Mechanism of Action

Studies examined a hypothesis regarding the drug's activity. Research evaluated the drug's affinity for the specific protein marker P2 in laboratory models, observing its binding characteristics. The researchers noted that the findings suggest a potential relationship between this action and the clinical results seen in patient trials.


Key Clinical Trials

Study 1: Initial Investigation of Outcomes

The initial Phase 3, randomized, controlled trial (n=500) examined effects on clinical outcomes in patients with X, focusing primarily on the measurement of inflammatory markers, as assessed by Cp.

  • Primary Outcome: The trial documented a lower average measure of disease activity over 6 months, compared to the placebo group.
  • Symptom Assessment: Research evaluated the timeline of changes in specific symptoms, including joint swelling and patient-reported pain scores.
  • Conclusion: This study provided the initial data used to assess the drug’s potential impact on the measured outcomes.

Study 2: Long-term Assessment

A follow-up study examined the long-term profile of the drug over a period of 12 months.

  • Safety Profile: Trial participants underwent safety and tolerability monitoring.
  • Interactions: Studies have explored potential interactions with grapefruit juice, though the clinical significance of these findings is not yet established.

Combination Therapy Research

Research has explored the use of this drug as a treatment option for more advanced cases, specifically in combination with standard-of-care drug Y.

  • Side Effect Mitigation: Studies examined whether the combination was associated with changes in measured side effect severity. The findings from this research were inconclusive.
  • Quality of Life: The results indicated a trend in the combined therapy group regarding quality of life, as measured by a standardized patient questionnaire.
  • Comparative Analysis: Studies assessed the treatment's impact and compared its findings with those from older methods. The available comparative data remains limited.

Key Studies & References

  1. A Guide to Regulatory Submissions in the US (FDA) & EU (EMA) (Template for general understanding of trial standards and regulatory context)

Frequently Asked Questions (FAQ)

Common questions about Uradex (FAQ)


Q: How long do the effects of a Uradex dose typically last?

According to the drug's known pharmacokinetics, the main therapeutic effect of a single oral dose typically lasts for about six hours. This is because the drug is considered to have a short half-life, meaning the body processes and eliminates it relatively quickly.


Q: What are common patient concerns about the long-term use of Uradex?

Clinical information indicates that Furosemide is often used for maintenance therapy for chronic conditions. Long-term use should be determined by a healthcare provider. This use requires careful clinical observation and regular laboratory monitoring to check for potential complications such as dehydration, electrolyte imbalances (such as low potassium), and changes in kidney function.


Q: How does Uradex relate to treatments for urinary tract issues?

Uradex's main job is to cause rapid and frequent urination (diuresis) to clear excess fluid. It is not prescribed for general urinary tract infections. Regulatory information also notes that it is strictly contraindicated (must not be used) in patients who are unable to produce any urine (a condition called anuria).


Q: Is it normal to feel slightly dizzy or tired when taking Uradex?

Yes, dizziness and fatigue (feeling low energy) are noted as common side effects of Furosemide, the active ingredient in Uradex. Dizziness is often related to a temporary drop in blood pressure when changing positions quickly, such as when standing up.


Q: Can Uradex cause issues with my stomach or digestion?

Official information indicates that Uradex can cause gastrointestinal side effects. These common issues include nausea, vomiting, diarrhea, constipation, and general abdominal cramping or an upset stomach.


Q: How long is a typical course of treatment with Uradex?

There is no single predetermined duration for Uradex treatment. For chronic conditions, the medication is often used as a continuous, long-term maintenance therapy. The patient’s need for the drug must be regularly reassessed by a healthcare professional.


Q: Can Uradex be taken while drinking coffee or energy drinks?

Caffeine is a stimulant that also acts as a diuretic, meaning it increases urine production. Combining this with Uradex, which is a potent diuretic, can lead to excessive fluid loss. Cautious and moderate intake of caffeine may be discussed with a healthcare provider due to the risk of dehydration.


Q: Does Uradex interact with herbal supplements like St. John's Wort or melatonin?

Official drug interaction information mentions that substances like natural licorice can enhance the potassium loss associated with Uradex. Certain other herbal supplements (such as dandelion or hibiscus) may also increase the dehydrating effect. No known clinically significant interactions have been found with Melatonin.


Q: What happens if I suddenly stop taking Uradex?

Suddenly stopping this medication can lead to a sudden return of fluid retention (edema or swelling). This can also cause blood pressure to increase again. A healthcare professional must be consulted before making any changes to the treatment plan.


Q: Does Uradex affect my ability to drive or operate machinery?

This medication may affect your coordination, reaction time, or judgment. Regulatory guidance indicates that patients should not drive or operate machinery until they know how this medication affects them, as it can cause dizziness or fainting.


Q: What should I do if the side effects from Uradex are bothersome?

Persistent or difficult-to-tolerate side effects should be discussed with a healthcare provider. They can offer advice on managing symptoms or may suggest possible dose adjustments. The medication should only be stopped as advised by a physician.


Q: Is there a generic version of Uradex available?

Yes. Uradex is the brand name for the active ingredient Furosemide, which is widely available as a generic medicine. The generic name Furosemide is recognized by regulatory authorities worldwide.


Q: What is the difference between brand-name Uradex and its generic equivalent?

According to regulatory sources like the FDA, generic Furosemide contains the exact same active ingredient at the same strength, dosage form, and route of administration as brand-name Uradex. Any differences are typically limited to inactive ingredients, packaging, or the appearance of the pill.


Q: How does the effectiveness of Uradex compare in different age groups?

Regulatory guidance requires that therapy in older adults begin at the lower end of the dosing range due to their increased risk of adverse effects like dehydration. Effectiveness is assessed by the prescribing physician, with dosing adjusted to the patient’s age and condition.


Q: Can Uradex cause changes in mood or sleep patterns?

Regulatory labels note that restlessness is a possible side effect. Due to the potential for frequent nighttime urination, taking the dose too close to bedtime may lead to sleep disturbances.


Q: Why do some health forums talk about a 'rebound effect' after stopping Uradex?

Some patients experience a temporary recurrence of their original condition, specifically fluid retention (edema or swelling), after discontinuing the medicine. This is related to the body's natural fluid balance systems readjusting.


Q: Is Uradex known to be safe for people with diabetes?

Official product information states that Uradex can increase blood glucose (sugar) levels and potentially alter glucose tolerance. Regular blood sugar monitoring may be necessary for diabetic patients, as official information indicates adjustments to diabetes medication may be required.


Q: How is Uradex usually metabolized by the body?

The active component, Furosemide, is processed by the body in part by the liver through a process called glucuronidation. About half of the dose is then eliminated by active excretion through the kidney.


Q: Can Uradex be crushed or split if swallowing is difficult?

Furosemide tablets are generally noted in patient guidelines to be safe to crush if necessary to help with swallowing. This modification must only be done as directed by a healthcare provider or pharmacist.

How should Uradex be stored and disposed of?

Uradex (Furosemide) must be stored strictly according to the conditions defined in the official regulatory labeling. This ensures the medicine remains stable and effective until its expiration date.

Storage and Handling Constraints

Requirement Category Furosemide Injection/Solution Furosemide Tablets
Temperature and Light Store at 20 C to 25 C (68 F to 77 F) (Controlled Room Temperature); Protect from light. Store at Room Temperature (or below 30 C); Protect from light.
Stability and Use Do not freeze. Discard any unused portion of a single-use vial or ampoule immediately. Store in the original container to maintain protection.
Child Protection Keep out of sight and reach of children. Keep out of sight and reach of children.

️ Official Disposal Instructions

Regulatory documents instruct that any unused or expired product must be disposed of in accordance with local requirements. Patients should not flush this medication down the toilet and should utilize a drug take-back program where available for safe disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Uradex found in:

A-Z Index: